Study provides insight on the value of a new orally-administered, selective P2X3 receptor antagonist antitussive that is under review by Health Canada.
Two plaintiffs are leading the suit filed on behalf of all the women from the Atikamekw First Nation who allegedly didn’t consent to a procedure that impaired their fertility.
At the heart of Novo Nordisk’s acquisition of Montreal-based Inversago Pharma is an oral agonist designed to block the receptor protein CB1, which plays an important role in metabolism and appetite regulation.
Made-in-Alberta technology is designed to make it easier for doctors to identify performance gaps in their practice, document improvements and get CME credits.